Bernd Eisele
Chief Executive Officer at Vakzine Projekt Management GmbH
Profile
Bernd Eisele is the CEO of Vakzine Projekt Management GmbH since 2014.
Prior to this, he worked as the Director-International Products at Abbott Products GmbH.
He also worked as a Project Manager-Clinical at Behringwerke AG from 1988 to 1996.
Dr. Eisele holds a doctorate degree from Ruprecht-Karls-Universität Heidelberg, which he received in 1986.
Bernd Eisele active positions
| Companies | Position | Start |
|---|---|---|
Vakzine Projekt Management GmbH
 Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Chief Executive Officer | 16/11/2009 |
Former positions of Bernd Eisele
| Companies | Position | End |
|---|---|---|
Behringwerke AG
 Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | Corporate Officer/Principal | 01/01/1996 |
| Abbott Products GmbH | Corporate Officer/Principal | - |
Training of Bernd Eisele
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | Health Technology |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Health Technology |
| Abbott Products GmbH |
- Stock Market
- Insiders
- Bernd Eisele
